Kenvue Inc. $KVUE Stock Holdings Increased by New York State Teachers Retirement System

New York State Teachers Retirement System boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,494,099 shares of the company’s stock after purchasing an additional 28,127 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of Kenvue worth $25,758,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Cornerstone Wealth Group LLC lifted its position in shares of Kenvue by 5.9% during the 1st quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock valued at $187,000 after acquiring an additional 606 shares during the last quarter. Physician Wealth Advisors Inc. grew its holdings in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the last quarter. Mill Creek Capital Advisors LLC grew its holdings in shares of Kenvue by 0.6% in the 4th quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock worth $2,143,000 after acquiring an additional 701 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management raised its position in shares of Kenvue by 0.3% during the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock worth $4,048,000 after purchasing an additional 712 shares during the period. Finally, Philip James Wealth Mangement LLC raised its position in shares of Kenvue by 5.5% during the fourth quarter. Philip James Wealth Mangement LLC now owns 13,888 shares of the company’s stock worth $240,000 after purchasing an additional 726 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

KVUE stock opened at $19.81 on Friday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $38.03 billion, a price-to-earnings ratio of 23.30, a P/E/G ratio of 1.50 and a beta of 0.47. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87. The firm has a 50 day moving average of $17.86 and a two-hundred day moving average of $17.71.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.24 EPS. As a group, equities analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is presently 97.65%.

Insider Activity

In related news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on KVUE shares. Barclays decreased their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. UBS Group decreased their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Finally, Citigroup dropped their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.